ICU sedation, delirium & recovery

Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial

Intensive Care MedPublished Randomised controlled trial

Authors' conclusion

These findings support the safety, validity, and feasibility of direct enteral challenge for critically ill patients with PEN-FAST assessed low-risk penicillin allergy.

Study context

Population
Critically ill ICU patients with a low-risk penicillin allergy label (PEN-FAST score < 3), four intensive care units (ICUs), Melbourne, Australia533 screened
Participants
80 patients
Comparison
Direct enteral penicillin challenge vs routine care
  • Direct enteral challengen = 40
Methodological detailspilot, safety and feasibility, multicentre (four ICUs), 1:1 randomisation, Patients reviewed at 24 h and 5 days after each challenge/observation
  • Pilot
  • Safety and feasibility
  • Multicentre (four ICUs)
  • 1:1 randomisation
  • Patients reviewed at 24 h and 5 days after each challenge/observation

Primary result

As reported in the abstract

Positive direct enteral challenge rate

Positive challenge rate with direct enteral challenge

2.5%

Further findings

Repeat challenge post-ICU (intervention arm)

Received a repeat challenge
32/40 (80%)
Positive repeat challenges
0

Penicillin received post-randomisation

Intervention arm received penicillin
13 (32%)
Control arm received penicillin
4 (10%)
Intervention vs control, OR [p = 0.019]
4.33 [1.27, 14.78]

Safety

Antibiotic-associated serious adverse events

None identified
0

Original publication

Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial. Intensive Care Med. Published 13 May 2024. doi:10.1007/s00134-024-07448-x

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.